Скачать или смотреть ARPI Toxicity and Tolerability: Treating the Whole Patient, Not Just the Disease

A regional roundtable discussion, moderated by Ulka Vaishampayan, MD, University of Michigan, offers a grounded, practical view of how academic oncologists are personalizing therapy across the prostate cancer continuum, from frontline treatment and ARPI selection to triplet therapy, biomarker integration, and emerging targeted agents like PARP inhibitors and radioligand therapy. Dr. Vaishampayan was joined by Robert Dess, MD, University of Michigan; Frank Cackowski, MD, PhD, Karmanos Cancer Institute; and three other individuals from University of Michigan: Phillip Palmbos, MD, PhD; Todd Morgan, MD; and Phoebe Tsao, MD.

In the fifth segment, the panel discusses considerations in selecting androgen receptor pathway inhibitors for metastatic prostate cancer, including efficacy, tolerability, mental health impacts, treatment holidays, and disparities in treatment outcomes among Black patients.